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ABSTRACT: Investigation of rare familial forms of renal cell
carcinoma (RCC) has led to the identification of genes such
as VHL and MET that are also implicated in the pathogen-
esis of sporadic RCC. In order to identify a novel candidate
renal tumor suppressor gene, we characterized the breakpoints
of a constitutional balanced translocation, t(5;19)(p15.3;q12),
associated with familial RCC and found that a previously
uncharacterized gene UBE2QL1 was disrupted by the chromo-
some 5 breakpoint. UBE2QL1 mRNA expression was down-
regulated in 78.6% of sporadic RCC and, although no intra-
genic mutations were detected, gene deletions and promoter
region hypermethylation were detected in 17.3% and 20.3%,
respectively, of sporadic RCC. Reexpression of UBE2QL1 in
a deficient RCC cell line suppressed anchorage-independent
growth. UBE2QL1 shows homology to the E2 class of ubiq-
uitin conjugating enzymes and we found that (1) UBE2QL1
possesses an active-site cysteine (C88) that is monoubiquiti-
nated in vivo, and (2) UBE2QL1 interacts with FBXW7 (an
F box protein providing substrate recognition to the SCF E3
ubiquitin ligase) and facilitates the degradation of the known
FBXW7 targets, CCNE1 and mTOR. These findings suggest
UBE2QL1 as a novel candidate renal tumor suppressor gene.
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Introduction
Renal cell carcinoma (RCC) is the most common adult renal
tumor and is genetically and histologically heterogeneous [Kovacs
et al., 1997; Maher, 2011]. Although only about 3% of RCC are
familial, these cases provide a paradigm of how the elucidation of
inherited causes of cancer can provide important insights into the
molecular mechanisms of sporadic cases. Thus, germline mutations
in the VHL (MIM #608537) tumor suppressor gene (TSG) cause
the familial cancer syndrome von Hippel–Lindau disease (MIM
#193300) and somatic VHL inactivation is found in at least 80% of
sporadic clear cell RCC [Banks et al., 2006; Foster et al., 1994; Gnarra
et al., 1994; Latif et al., 1993; Maher et al., 1991]. The identification
of the VHL gene product, pVHL, and its function as the substrate
recognition unit of the E3 ubiquitin ligase complex that regulates the
proteolytic degradation of the α-subunits of the hypoxia inducible
transcription factors HIF-1 and HIF-2, led to recognition of the
fundamental role of hypoxia inducible gene pathway activation in
the pathogenesis of familial and sporadic RCC [Cockman et al.,
2000; Maxwell et al, 1999]. However, not all RCC is associated
with HIF dysregulation and alternate pathways of sporadic RCC
tumorigenesis remain to be identified.
Familial RCC is genetically heterogeneous and many patients
do not have mutations in known inherited RCC genes [e.g., VHL,
FH (MIM #136850, #150800), FLCN (MIM #607273, #135150),
MET (MIM #164860, #605074), SDHB (MIM #185470, #115310,
#171300) [Maher, 2011; Ricketts et al., 2008; Woodward et al.,
2008]. It has long been recognized that inherited RCC may be asso-
ciated with constitutional chromosome translocations, particularly
of chromosome 3 [Cohen et al., 1979]. To date, 13 RCC-associated
translocations have been described and, in some cases, character-
ization of the breakpoints has led to the identification of candi-
date TSGs (e.g., FHIT, LSAMP, NORE1) that have been implicated
in sporadic renal tumorigenesis [Cohen et al., 1979; Kuiper et al.,
2009; Woodward et al., 2010]. Thus, although the association of con-
stitutional chromosome 3 translocations with RCC has been well
established [Woodward et al., 2010], the significance of
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nonchromosome 3 constitutional translocations is more difficult
to evaluate. Here, we describe a novel nonchromosome 3 consti-
tutional translocation associated with an inherited predisposition
to RCC and investigate the function and role in sporadic renal tu-
morigenesis of UBE2QL1, a previously uncharacterized gene that is
disrupted by the translocation.
Materials and Methods
Cell Lines and Clinical Samples
An EBV-transformed lymphoblastoid cell line was established
from the index case of the family with the t(5;19)(p15.3;q12) by
the European Cell and Culture Collection, Porton Down, UK and
maintained in RPMI 1640 (Invitrogen, Paisley, UK) supplemented
with 10% FCS at 37◦C and 5% CO2. RCC cell lines KTCL-26, SKRC
45, SKRC 54, Caki-1, 786-0, KTCL-140, RCC4, SKRC 39, SKRC 47,
SKRC 18, UM-RC-3, RCC48, RCC1, RCC12, A498, ACHN, 769-P,
CAL-54 were routinely maintained in DMEM (Invitrogen, Paisley,
UK) supplemented with 10% FCS at 37◦C and 5% CO2.
Characterization of t(5;19)(p15.3;q12) Breakpoints
Flow-sorted derivative chromosomes were initially hybridized
onto BAC arrays as described [Fiegler et al., 2003], which resolved
the breakpoints to within 1 Mb. This information was used to de-
sign custom arrays (Roche-Nimblegen, Welwyn Garden City, UK)
to further refine the breakpoints, which were then characterized by
PCR and Sanger sequencing.
Immunohistochemistry
Immunohistochemistry was performed using 5 μm tumor sec-
tions. Specimens were deparaffinized in xylene and alcohol. Antigen
retrieval was achieved by water bathing the slides in low pH target
retrieval solution at 98◦C and treated with 1% H2O2 in 98% alco-
hol to block endogenous peroxidase. Slides were then incubated at
room temperature for 1 hr with primary antibody and treated with
the EnVision + kit (Dako, Cambridgeshire, UK). Slides were then
visualized using diaminobenzidine and counterstained in Mayer’s
hematoxylin solution (Sigma–Aldrich, Poole, UK).
VHL and UBE2QL1 Mutation Analysis
DNA was extracted from peripheral leucocytes using the
Nucleon BACC2 kit (GE Healthcare [Amersham Biosciences],
Buckinghamshire, UK). UBE2QL1 (NM 001145161.2) and VHL
(NM 000551.3) were screened for mutations by PCR amplification
of all coding exons and exon–intron boundaries followed by a termi-
nator cycle sequencing reaction containing PCR products, BigDye
Terminator v3.1 and 5x sequencing buffer (Applied Biosystems).
PCR conditions and Primer sequences are available on request.
Products were run on an ABI 3730 automated sequencer (Applied
Biosystems).
Quantitative Real-Time PCR
RNA was extracted from renal tissue following a traditional phe-
nol:chloroform RNA extraction technique. cDNA was derived from
1 μg of RNA template using SuperScript R© II Reverse Transcriptase
and random hexamers following manufacturer’s instructions (In-
vitrogen, Paisley, UK). Taqman quantitative real-time (qRT)-PCR
was undertaken using Gene Expression Taqman Assays (20× FAM
dye-labeled) for UBE2QL1 and β-actin along with Taqman Univer-
sal Master Mix II (10×) (Applied Biosystems). Fifty nanograms of
cDNA samples was loaded in triplicate onto a 96-well plate along
with negative controls containing no cDNA. β-actin probes were
used as internal controls and were loaded in triplicate on the same
plate for each sample. PCR conditions were used as recommended
by Applied Biosystems. Reactions were run on 7500 Real-Time PCR
System (Applied Biosystems).
5-Aza-2′-Deoxycytidine Treatment
The demethylating agent 5-Aza-2′-deoxycytidine (Sigma–
Aldrich, Poole, UK) was freshly prepared in double-distilled H2O
and filter sterilized. Cell lines were plated in 75 cm2 flasks in DMEM
supplemented with 10% FCS at differing densities. Twenty-four
hours later, cells were treated with 5 μmol/l 5-Aza-2′-deoxycytidine.
The medium was changed 24 and 72 hr after treatment. RNA was
prepared 5 days after treatment using RNABee (AMS Biotechnol-
ogy, Abingdon, UK). UBE2QL1 expression was detected by re-
verse transcriptase-PCR. Primers and PCR conditions available on
request.
Bisulfite Modification and Methylation Analysis
Bisulfite modification was undertaken using the EpiTect Bisulfite
Kit following manufacturer’s instructions (QIAGEN, Crawley, UK).
The UBE2QL1 CpG island was identified on the human genome
browser (http://genome.ucsc.edu/) and the promoter region am-
plified from RCC cell lines and primary tumors. Primer sequences
are available on request. PCR products were digested with BstUI
and visualized on a 2% agarose gel. Bisulfite-modified products
selected for sequencing were cloned into the pGem R©-T Easy Vec-
tor (Promega, Southampton, UK) according to the manufacturer’s
instructions. Up to 12 individual colonies were chosen for initial
amplification followed by sequencing using vector specific primers.
Multiplex Ligation-Dependent Probe Amplification
Multiplex ligation-dependent probe amplification (MLPA)
analysis to detect copy number changes was performed us-
ing the SALSA MLPA P300-A1 human DNA reference-2
kit according to manufacturer’s instructions (MRC-Holland,
Amsterdam, Netherlands). Custom UBE2QL1 probes were
designed using MRC-Holland guidelines (http://www.mlpa.
com/WebForms/WebFormMain.aspx) in regions with no known
polymorphisms as determined using the SNP database
(http://www.ncbi.nlm.nih.gov/SNP/). PCR products were sepa-
rated using an automated 3730 DNA Analyzer and analyzed us-
ing GeneMapper R© ID v3.1 (Applied Biosystems). Peak heights for
each probe were intrasample normalized using the peak heights of
reference probes in the same sample. Probes that deviated from
adjacent reference probes ≥25% were highlighted. An average de-
viation of ≥30% from adjacent reference probes for all UBE2QL1
probes or single exon probes indicated a whole gene or exon deletion
respectively.
Plasmid Constructs
UBE2QL1 expression constructs were made by cloning the full
length human coding region amplified from RCC cell lines into the
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EcoR1–BamH1 sites of pcDNA3.1 (Invitrogen, Paisley, UK), pFLAG-
CMV4 (Sigma–Aldrich, Poole, UK), and pCMV-myc (Clontech,
Saint-Germain-en-Laye, France) vectors. The FBXW7 coding re-
gions were cloned into p3XFLAG-myc-CMV-24 (Sigma–Aldrich,
Poole, UK) at the following sites: FBXW7α in Hind3–EcoRI; and
FBXW7γ in Hind3–Xba1. The FBXW7 constructs were a gift from
Markus Welcker and the HIS6-ubiquitin vector a gift from Dirk
Bohmann. Stop codons were included in the FBXW7 coding re-
gions so the myc tag was not incorporated. The point mutants for
UBE2QL1 were generated by PCR-based site-directed mutagene-
sis using the QuikChange Lightning Site-Directed Mutagenesis Kit
following manufacturer’s instructions. Plasmids were verified by
sequencing.
Antibodies
The following antibodies were used: monoclonal anti-FLAG M2
[1:1,000 dilution Western blot (WB), 1:2,000 dilution immunofluo-
rescence (IF); Sigma–Aldrich, Poole, UK]; monoclonal anti-β-actin
(1:10,000 dilution WB; Sigma–Aldrich, Poole, UK), monoclonal
antitubulin (1:10,000 dilution WB and IF; Sigma–Aldrich, Poole,
UK), anti-myc (1:1,000 dilution WB and IF; Sigma–Aldrich, Poole,
UK), anti-HIS6 (1:1,000 dilution; Abcam, Cambridge, UK), anti-
mTOR (1:1,000 dilution; Cell Signaling, Hitchin, UK), anti-CCNE1
[1:1,000 dilution WB, 1:20 dilution immunohistochemistry (IH);
Abcam, Cambridge, UK], monoclonal anti-CA9 (1:400 dilution IH;
Abcam, Cambridge, UK), monoclonal anti-CCND1 (1:25 dilution
IH; NeoMarkers, Fremont, CA).
Transfection
HEK-293, HeLa, SKRC 39, and SKRC 47 cells were transfected
with various plasmids using Fugene Transfection Reagent (Roche)
according to the manufacturer’s protocol.
Colony Formation Assays
5 × 105 of SKRC 39 and SKRC 47 cells were transfected with
either 2 μg of empty vector or expression vector. Forty-eight hours
after transfection cells were seeded in a serial dilution and main-
tained in 10 ml DMEM with 10% FCS supplemented with 1 mg/ml
G418 (Sigma–Aldrich [Life Technologies], Poole, UK). Twenty-one
days after initial seeding surviving colonies were stained with 0.4%
crystal violet (Sigma–Aldrich, Poole, UK) in 50% methanol. Each
transfection was undertaken in triplicate.
Anchorage-Independent Growth Assays
RCC clones of SKRC 47 stably expressing FLAG-UBE2QL1 or
empty vector control were suspended in 2 ml DMEM, 10% FCS,
3% agar. Cells were maintained by addition of 200 μl of DMEM,
10% FCS, supplemented with 1 mg/ml of G418 weekly. Colonies
measuring ≥100 μm were counted following 5 weeks of incu-
bation in soft agar. Each experiment was undertaken six times
simultaneously.
Coimmunoprecipitation
Transfected cells were lysed with NETN buffer [50 mM Tris–
HCl at pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic
acid (EDTA), 1% Nonidet P-40] and whole-cell lysates obtained
by centrifugation were incubated with 10 μg of specified antibody
bound to protein G Dynabeads (Invitrogen, Paisley, UK) for 2 hr at
4◦C. The beads were then washed with NETN 4× buffer and applied
to SDS-PAGE. Immunoblotting was carried out following standard
protocols.
His Pull-Down Assay
Following transfection, HEK-293 cells were lysed with 1× bind-
ing/wash buffer (50 mM Na-phosphate at pH 8.0, 300 mM NaCl,
0.01% Tween-20) containing 1% Triton X-100. The whole-cell
lysates obtained by centrifugation were incubated with 2 mg of
His Tag Isolation and Pulldown Dynabeads R© (Invitrogen, Paisley,
UK) for 1 hr at 4◦C. The beads were then washed four times with
1× pull-down buffer (3.25 mM Na-phosphate at pH 7.4, 70 mM
NaCl, 0.01% Tween-20) and eluted with 50 μl of His elution buffer
(300 mM imidazole, 50 mM Na-phosphatase pH 8.0, 300 mM NaCl,
0.01% Tween-20). Laemmli sample buffer was added to the elutes
with or without β-mercaptoethanol as indicated and SDS-PAGE
undertaken. Immunoblotting was carried out following standard
protocols.
Reticulocyte Lysate Protein Transcription/Translation
Wild-type UBE2QL1 and the UBE2QL1 C88A mutant were syn-
thesized with L-α-[35S]-methionine using the pcDNA3.1 constructs
as template and the TNT R© Coupled Reticulocyte Lysate System fol-
lowing manufacturer’s instructions (Promega, Southampton, UK).
Immunofluorescence
Cells grown on cover-slips were washed three times with PBS then
fixed with chilled methanol for 10 min at 4◦C. Cells were then washed
three times in PBS and blocked with 1% BSA in PBS for a minimum
of 30 min. Primary antibody diluted in 1% BSA in PBS was added to
the cells and incubated for 1 hr at room temperature. After washing
with PBS, cells were incubated with either goat antimouse IgG Alexa
Fluor 594 or goat antirabbit IgG Alexa Fluor488 (Invitrogen, Paisley,
UK) secondary antibodies at room temperature for 1 hr. After a
final wash with PBS, cover-slips were mounted with 4,6-diamidino-
2-phenylindole (DAPI) nucleic acid stain (Invitrogen, Paisley, UK).
Cells were analyzed using a fluorescence light microscope, Axiovert
200 (Zeiss).
Degradation Assay
HeLa cells were transfected with either myc-UBE2QL1 or empty
vector control. At 24 hr posttransfection, cells were treated with
cyclohexamide (Sigma–Aldrich, Poole, UK) at a concentration of
100 μg/ml and collected at the following times afterward: 0; 2; 4; 6;
8; and 10 hr. Whole-cell extracts were prepared by RIPA lysis (50 mM
Tris–HCl pH8, 150 mM NaCl, EDTA 1 mM, 0.5% Na-deoxycholate,
1% NP-40, and 0.1% SDS) and centrifugation. Ten micrograms of
protein was analyzed by SDS-PAGE and immunoblotting with the
indicated antibodies.
Statistical Analysis
The data are expressed as mean ± SEM from a suitable number
of experiments as indicated in the figure legends. Statistical analysis
was by the two-tailed Student’s t-test and P < 0.05 was considered
significant.
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Results
Clinical Case Report
A family with an apparent genetic predisposition to RCC was
referred to our clinic. The index case presented at the age of 35 years
with separate foci of an 18 mm oncocytoma and a 5 mm chromo-
phobe RCC in her left kidney (Supp. Fig. S1). Subsequently, her
sister was diagnosed at the age of 36 years with two RCC (a 2.5 cm
clear cell and 1.0 cm chromophobe) in her right kidney and, 2 years
later, multiple oncocytomas (n = 4, 0.6–1.8 cm) in her left kidney.
Their deceased mother was reported to have developed a carcinoid
tumor at the age of 44 years and their maternal aunt reported to have
died from an RCC (age unknown). No mutations were detected in
either VHL or FLCN but a constitutional balanced translocation,
t(5;19)(p15.3;q12), was identified in both sisters but not in the two
unaffected brothers. We surmised that the constitutional transloca-
tion was responsible for the family history of renal tumorigenesis
and proceeded to characterize the translocation breakpoints.
Characterization of t(5;19)(p15.3;q12) Breakpoints
We initially mapped the breakpoints by hybridization of amplified
flow sorted derivative chromosomes onto the whole genome tiling
path array held at the Wellcome Trust Sanger Institute [Fiegler et al.,
2003]. The localizations of the breakpoints were further refined
using a custom designed oligonucleotide CGH array (Nimblegen,
OH) followed by direct genomic sequencing (following long range
PCR amplification) across the breakpoints (Supp. Fig. S2A and B;
Fig. 1A and B). The chr19 breakpoint was defined at 30,279,438
on der(19) and at 30,279,436 on der(5) and the chr5 breakpoint
at 6,456,990 on der(19) and at 6,456,998 on der(5) (hg19). There
were four bases, CCTG, present at the der(19) breakpoint which are
common to both chr19q and chr5p in the breakpoint region and
it was not possible to assign their chromosomal origin. The chr19
breakpoint was associated with a duplication of either GGACCTG
(30,279,436–442) or GGA (30,279,436–438) and the chr5 break-
point with a deletion of either CAGGGCT (6,456,991–997) or GCT
(6,456,995–997) depending on the origin of the four common bases.
We noted the chr5 breakpoint was found to disrupt the first intron of
a previously uncharacterized gene, UBE2QL1, so that the 5′ region,
exon 1, and part of intron 1 were translocated onto chr19. No gene
was disrupted by the chromosome 19 breakpoint. To determine if
there was evidence of UBE2QL1 functioning as a classical TSG (as
for VHL), we investigated whether allele loss might occur in a renal
tumor from the family. As one allele of UBE2QL1 had been found
to be disrupted in the t(5;19)(p15.3;q12) carriers, we investigated
whether there was loss of the second allele in the t(5;19)(p15.3;q12)
associated renal tumors. We did not find evidence of loss of chr5
but did detect an intragenic deletion of UBE2QL1 exon 1 in an
oncocytoma from patient III:II (Fig. 1C).
Identification of UBE2QL1 Genetic and Epigenetic
Alterations in Sporadic RCC
As some inherited RCC genes (e.g., VHL, MET) have also been
implicated in the pathogenesis of sporadic RCC, we therefore in-
vestigated whether UBE2QL1 also has a role in sporadic RCC tu-
morigenesis. Initially, we investigated UBE2QL1 mRNA expression
levels and found loss of expression in 11/18 (61.1%) RCC cell lines
(Supp. Fig. S3A) and, compared with corresponding normal tissue,
in 22/28 (78.6%) sporadic RCC (Fig. 2A). Although direct sequenc-
ing of UBE2QL1 in 17 RCC cell lines and 116 sporadic RCC did not
detect intragenic mutations, analysis for copy number abnormal-
ities using a custom-designed MLPA assay detected heterozygous
UBE2QL1 deletions in 8/49 (16.3%) sporadic RCC (Fig. 2B). The
MLPA detected deletions were confirmed by loss of heterozygosity
at closely linked microsatellite markers (D5S2505 and D5S2054) in
three informative cases (Supp. Fig. S4).
Epigenetic inactivation by promoter region hypermethylation
is a common mechanism of TSG inactivation in renal and
other cancers. A UBE2QL1 CpG island was detecting using
http://cpgislands.usc.edu/ set to the standard criteria [Takai and
Jones, 2002] and treatment with the demethylating agent 5-Aza-2′-
deoxycytidine (5-Aza) in the 11 UBE2QL1 silenced RCC cell induced
reexpression of UBE2QL1 in five (Supp. Fig. S3B). Methylation of
the UBE2QL1 5′ CpG island (Supp. Fig. S5) was confirmed by COm-
bined Bisulfite Restriction Analysis (COBRA) in the five RCC cell
lines with reduced expression levels, suggesting UBE2QL1 gene ex-
pression is dysregulated by CpG island methylation (Supp. Fig. S3C).
We therefore investigated whether UBE2QL1 promoter hyperme-
thylation was present in primary RCC and we detected hyperme-
thylation in 14/66 (21.2%) primary RCC tested (but not in matched
normal kidney where available) (Fig. 2C and D). UBE2QL1 mRNA
expression data were available for eight RCC cases with promoter
region hypermethylation and each tumor demonstrated ≥60% re-
duction in expression compared with matched normal tissue. 2/41
tumors with both COBRA and MLPA analysis showed homozygous
inactivation of UBE2QL1.
UBE2QL1 Suppresses RCC Cell Growth
To determine if UBE2QL1 suppresses growth of RCC cells
we transfected wild-type UBE2QL1 expression plasmids into the
UBE2QL1 silenced RCC cell lines SKRC 47 and SKRC 39 (data
not shown) and undertook colony formation assays. Reexpression
of UBE2QL1 was associated with a significant (57.5% and 54.6%,
respectively) reduction in colonies compared with those trans-
fected with empty plasmid in both SKRC 47 and SKRC 39 cells
(Fig. 3A). We then assessed the effect of reexpression of UBE2QL1
on anchorage-independent growth in a soft agar colony formation
assay. Stably transfected SKRC 47 cells expressing UBE2QL1 or EV
were compared following incubation in soft agar for five weeks.
Compared with EV, there was a statistically significant 77% reduc-
tion in colony growth in UBE2QL1 transfected cells (Fig. 3B).
UBE2QL1 Associated Tumorigenesis is not Associated with
HIF Dysregulation
As HIF dysregulation plays a key role in VHL-associated renal
tumorigenesis, we investigated expression of the HIF-1 and HIF-2
targets [carbonic anhydrase 9 (CA9) and cyclin D1 (CCND1), re-
spectively] in three t(5;19)(p15.3;q12) associated renal tumors from
individuals III:1 and III:2 (two oncocytomas and one chromophobe
RCC). In contrast to control VHL-inactivated RCC, none of the
tumors demonstrated upregulation of CA9 or CCND1 protein ex-
pression suggesting a HIF-independent mechanism of UBE2QL1
tumorigenesis (Supp. Fig. S6).
UBE2QL1 is an E2 Ubiquitin Conjugating Enzyme
The amino-acid sequence of UBE2QL1 shows homology to the E2
class of ubiquitin conjugating enzymes which are characterized by a
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Figure 1. Characterization of t(5;19)(p15.3;q13.1) breakpoints and identification of an intragenic deletion of UBE2QL1 in a t(5;19)(p15.3;q13.1)
associated renal tumor. A: Sequence of der(5) breakpoint. B: Sequence of der(19) breakpoint. There are four bases, CCTG, for which it was not
possible to ascribe their chromosomal origin. C: Multiplex ligation-dependent probe amplification bar chart showing deviation of UBE2QL1 probes
from reference probes for exons 1 and 2 in a t(5;19)(p15.3;q13.1) associated renal oncocytoma. There is a significant deviation for exon 1 probes
indicating a deletion of exon 1 (unpaired t-test, error bars = SEM, ∗∗P < 0.01).
150 residue catalytic core domain, known as the Ubc domain, con-
taining a central active-site cysteine, which binds ubiquitin through
a thiolester bond [Wenzel et al., 2010] (Fig. 4A). E2s form an impor-
tant component of the ubiquitylation cascade whereby ubiquitin is
initially activated by an E1 enzyme followed by transfer to an E2 and,
once charged with ubiquitin, the E2 interacts with an E3 ubiquitin
ligase to ubiquitylate the protein substrate with substrate fate being
determined by the nature of the ubiquitin chain(s) formed [Ikeda
and Dikic 2008; Pickart 2001].
We hypothesized that UBE2QL1 functions as an E2 conju-
gating enzyme binding ubiquitin via a thiolester bond through
the cysteine residue at position 88. We initially expressed wild-
type UBE2QL1, and a predicted nonfunctional p.Cys88Ala (C88A)
UBE2QL1 mutant, using L-α-[35S]-methionine and an in vitro tran-
scription/translation rabbit reticulocyte lysate system that supports
ubiquitin conjugation. Consistent with our idea that cysteine 88 of
UBE2QL1 binds ubiquitin, wild-type UBE2QL1 migrated with a
band size of 26 kDa, whereas the UBE2QL1 C88A mutant migrated
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Figure 2. Identification of UBE2QL1 genetic and epigenetic alterations in sporadic RCC. A: Quantitative real-time PCR bar chart showing % of
UBE2QL1 expression in 28 sporadic RCC compared with corresponding normal renal tissue (n = 3). β-Actin was used as an internal control. 22/28
tumors showed a >40% loss of expression. B: Multiplex ligation-dependent probe amplification bar chart showing deviation of all UBE2QL1 probes
from reference probes in eight sporadic RCC. A significant deviation of all the UBE2QL1 probes from the reference probes indicates a complete
gene deletion (unpaired t-test, error bars represent SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). C: BstU1 digest of bisulfite modified DNA (COBRA)
for the UBE2QL1 CpG island in six sporadic RCC. Methylation was detected in the tumor samples (T) shown but not in either corresponding (N)
or unrelated (NN) normal renal tissue. “−” no BstU1 added, “+” BstU1 added. “−ve” no DNA template, “+ve” PCDNA3.1 positive control for in
vitro methylation. Smaller bands in both “−” and “+” lanes represent primer dimer. D: Schematic diagrams representing sequence analysis of the
UBE2QL1 promoter region following cloning of bisulfate-modified DNA. CpG dinucleotides analyzed are numbered 1–47. Vertical lines represent
individual CpGs, black circles represent methylated CpGs, and open circles unmethylated CpGs. The methylation index (MI) is calculated as a
percentage of all the methylated CpGs/total number of CpGs sequenced.
with a size of 18 kDa (Fig. 4B). These findings were consistent
with the hypothesis that p.Cys88 binds ubiquitin and we then pro-
ceeded to investigate whether UBE2QL1 binds ubiquitin directly
in vivo.
We transfected HEK-293 cells with expression plasmids encoding
HIS6–ubiquitin and FLAG-wtUBE2QL1 or FLAG-UBE2QL1C88S or
FLAG-UBE2QL1C88A. The p.Cys88Ser mutant was investigated as
the thiolester bond which forms between an E2 active-site cysteine
and ubiquitin, while essential for catalysis, is often not able to with-
stand cell lysis procedures, whereas ubiquitin interaction with serine
forms a more stable oxy-ester complex and is predicted to enhance
ubiquitin binding [Wada et al., 2000].
Ubiquitin binding was assessed by pull-down with Dynabeads R©
and blotting with antibodies against the HIS6 and FLAG tags in both
the absence and presence of β-mercaptoethanol (which reduces thi-
olester bonds). In the absence of β-mercaptoethanol, wtUBE2QL1
and UBE2QL1C88S bound ubiquitin with the C88S showing en-
hanced avidity for ubiquitin relative to wtUBE2QL1 (Fig. 4C). Of
note, UBE2QL1 bound monoubiquitin and did not form polyu-
biquitin chains. In the presence of β-mercaptoethanol, and con-
sistent with observations for some other ubiquitin conjugating en-
zymes, wtUBE2QL1 lost its ability to bind ubiquitin, whereas the
UBE2QL1C88S mutant retained its ability to bind ubiquitin (Fig. 4C).
These results indicate that UBE2QL1 is monoubiquitinated in vivo
through the active-site cysteine, C88.
Ub Binding is Necessary for UBE2QL1-Mediated RCC Cell
Growth Suppression
Having demonstrated that UBE2QL1 binds monoubiquitin at its
active-site cysteine, we then proceeded to determine if this binding
was essential for the growth suppressive function of UBE2QL1 in the
soft agar colony formation assay. Stably transfected SKRC 47 cells
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Figure 3. UBE2QL1 shows growth suppression and inhibition of anchorage-independent growth. A: Colony growth assays with SKRC 47 RCC
cell lines stably expressing pFLAG-CMV-4 (EV) or pFLAG-CMV-4-wtUBE2QL1 (UBE2QL1). Colonies (>100 μm) were manually counted blindly after
4 weeks (t-test, error bars = SEM, ∗∗∗P < 0.0001, n = 3). SKRC 47 cells not expressing UBE2QL1 (EV) produced significantly more large (>100 μm)
colonies compared with those expressing exogenous UBE2QL1 (UBE2QL1). Below the graph is a representative plate showing colony reduction
after UBE2QL1 reexpression. B: Stable clones of SKRC 47 pFLAG-CMV-4-wtUBE2QL1 and pFLAG-CMV-4 were seeded at the same density into soft
agar and incubated for five weeks. SKRC 47 cells not expressing UBE2QL1 (EV) produced significantly more large (>100 μm) colonies compared
with cells expressing exogenous UBE2QL1 (UBE2QL1) (t-test, error bars = SEM, ∗∗∗P < 0.0001, n = 6). Below the graph are representative images
of clones following 5 weeks of incubation (×100 magnification). C: Stable clones of SKRC 47 pFLAG-CMV-4-UBE2QL1C88A and pFLAG-CMV-4 were
seeded at the same density into soft agar and incubated for five weeks. SKRC 47 cells expressing UBE2QL1C88A (UBE2QL1C88A) produced similar
numbers of large (>100 μm) colonies compared with cells not expressing UBE2QL1 (EV) (t-test, error bars = SEM, P = 0.3677, n = 6). Below the graph
are representative images of clones following 5 weeks of incubation (×100 magnification).
expressing either the nonfunctional p.Cys88Ala (C88A) UBE2QL1
mutant or EV were compared following incubation in soft agar for
5 weeks. There was no significant difference in the colony counts,
indicating that the growth suppressive function of UBE2QL1 is
dependent upon its ability to bind ubiquitin at the C88 position
(Fig. 3C).
UBE2QL1 Interacts with FBXW7
The interaction between E2 enzymes and E3 ligases is often weak
(this enables the efficient dissociation after ubiquitin transfer of the
E2 enzyme from the E3 ligase, to make way for a new E2-ubiquitin
bound molecule) and many E2–E3 complex interactions are not de-
tectable using normal protein interaction detection methods, such as
yeast-2-hybrid and immunoprecipitation/mass spectrometry. Fur-
thermore, most E3 ligases will only bind ubiquitin bound E2 en-
zymes [Deshaies and Joazeiro, 2009]. We did not detect a UBE2QL1
E3 ligase binding partner through conventional detection methods
and so undertook an in silico search (http://elm.eu.org/) for poten-
tial binding motifs in the full length UBE2QL1 protein sequence.
This revealed a consensus sequence, VTPPVS at positions 154–159,
which has been proposed to act as an FBXW7 recognition motif
(Fig. 4A) [Nash et al., 2001]. FBXW7 is an F-box protein that pro-
vides substrate recognition to the CUL1-SKP1-RBX1 SCF ubiquitin
ligase (SCFFBXW7) complex [Bai et al., 1996; Feldman et al., 1997;
Skowyra et al., 1997; Skowyra et al., 1999] and has previously been
reported to be somatically mutated in human cancers and to be
disrupted by a RCC-associated constitutional translocation [Davis
and Tomlinson 2012; Kuiper et al., 2009; Tan et al., 2008; Welcker
and Clurman 2008].
To investigate whether UBE2QL1 and FBXW7 might interact,
we investigated the intracellular localization of myc-UBE2QL1
and FLAG-α/γ -FBXW7 (there are no suitable antibodies for the
endogenous proteins) in HeLa cells. Previously, the α and γ
isoforms of FBXW7 were shown to be present in the nucleus
[Welcker and Clurman, 2008]. We confirmed these findings (data
not shown) and detected nuclear colocalization of UBE2QL1 with
both the α and γ isoforms of FBXW7 (Fig. 5A). Furthermore,
after transfection of HEK293 cells with FLAG-α/γ -FBXW7 and
myc-UBE2QL1, immunoprecipitation and immunoblot analysis,
FBXW7 and UBE2QL1 were found to coimmunoprecipitate with
antibodies against either the FLAG or myc tag and immunoblotting
with the reciprocal antibody (Fig. 5B).
Effect of UBE2QL1 on Expression of FBXW7 Targets
Previous studies have reported that FBXW7 regulates expres-
sion of CyclinE1 (CCNE1) and mTOR [Koepp et al., 2001; Mao
et al., 2008]. We proceeded to investigate whether UBE2QL1 status
might influence CCNE1 and mTOR expression in the UBE2QL1
deficient RCC cell lines SKRC 47 and SKRC 39. Protein lysates
from the UBE2QL1 or EV stably transfected SKRC 47 and SKRC
39 cells were used to compare protein expression levels of mTOR
and CCNE1. Both CCNE1 and mTOR expression was reduced in
UBE2QL1 expressing cells compared with EV controls (Fig. 6A).
We then investigated the degradation of both FBXW7 targets in
SKRC 47 cells after transient transfection with myc-UBE2QL1 or
EV and addition of the protein synthesis inhibitor, cyclohexam-
ide. A serial reduction in both mTOR and CCNE1 protein levels
was detected after transfection with the myc-UBE2QL1 plasmid (as
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Figure 4. UBE2QL1 binds monoubiquitin in vivo. A: Schematic diagram of UBE2QL1 showing the ubiquitin conjugating (Ubc) domain containing
an active-site cysteine at residue 88 and a FBXW7 recognition motif (residues 154–159). B: Transcription/translation lysate system produces
wtUBE2QL1 at ∼26 kDa and UBE2QL1C88A at ∼18 kDa suggests wtUBE2QL1 is monoubiquitinated (ubiquitin Mr 8.5 kDa). C: HEK-293 cells were
transfected with either FLAG-tagged UBE2QL1-wt or UBE2QL1-C88S or FLAG-UBE2QL1-C88A mutants and either His6-tagged ubiquitin (His-Ub) or
empty vector (His-EV). His pulldown followed by immunoblot (IB) analysis demonstrated that UBE2QL1-wt is monoubiquitinated in vivo (bands at
Mr of ∼26 kDa). Input levels of UBE2QL1-wt, UBE2QL1-C88S, and UBE2QL1-C88A in the cell lysate are indicated (bands at Mr of ∼18 kDa).
compared with cells transfected with EV) indicating that degrada-
tion of these FBXW7 targets is enhanced by UBE2QL1 (Fig. 6B).
In view of the in vitro evidence that UBE2QL1 regulated CCNE1
expression, t(5;19)(p15.3;q12) associated renal tumors from indi-
viduals III:I and III:II (two oncocytomas and one chromophobe
RCC) were stained for CCNE1 expression and increased expression
detected (Supp. Fig. S7).
Discussion
We identified an uncharacterized gene, UBE2QL1, that was dis-
rupted by a t(5;19)(p15.3;q12) associated with a familial predispo-
sition to RCC, and demonstrated that UBE2QL1 has tumor sup-
pressor activity and is inactivated in a subset of sporadic RCC by
promoter region hypermethylation and/or deletions. Interestingly,
although the mechanism of tumor suppression of several inherited
RCC genes (e.g., VHL, FH, FLCN, and SDHB) has been linked to
HIF-1/HIF-2 related pathways, we did not identify evidence of HIF
target dysregulation in t(5;19)(p15.3;q12) associated renal tumors
(and there was no relationship between UBE2QL1 status and the
presence or absence of a VHL mutation in sporadic RCC). The
function of UBE2QL1 has not previously been characterized but
it shows homology to the E2 class of ubiquitin conjugating en-
zymes and we found evidence of UBE2QL1 monoubiquitination
(consistent with an E2 function). Furthermore, after identifying
by computational analysis a candidate FBXW7 recognition motif
in UBE2QL1 we found evidence for UBE2QL1 interacting with
FBXW7 and regulating expression of the FBXW7 targets CCNE1
and mTOR. Further investigations are required to elucidate the pre-
cise function of UBE2QL1 and the relationship between UBE2QL1
growth suppression, E2 activity and FBXW7 function. Although
components of E3 ubiquitin complexes (e.g., VHL and FBXW7)
have been clearly implicated in tumorigenesis [Bernassola et al.,
2008; Sun, 2003; Sun 2006], there is relatively little information
regarding the potential role of E2 conjugating enzymes, though in-
creased expression of some (e.g., UbcH10 and E2-EPF) has been
described in some cancers [Okamoto et al., 2003; Roos et al., 2011;
Seghatoleslam et al., 2012; Tedesco et al., 2007]. Based on the known
tumor suppressor function of FBXW7 and the previous report of an
RCC associated constitutional translocation that disrupts FBXW7,
we suspect that UBE2QL1 inactivation compromises FBXW7 func-
tion although further studies are required to elucidate the exact
mechanism. However, it is likely that further UBE2QL1 binding
partners remain to be identified and their role in RCC tumorigene-
sis elucidated.
HUMAN MUTATION, Vol. 34, No. 12, 1650–1661, 2013 1657
Figure 5. UBE2QL1 colocalizes and immunoprecipitates with FBXW7. A: HeLa cells were transfected with either myc-UBE2QL1 alone and stained
with antibodies against α-tubulin (red) and myc (green), which showed a nuclear localization of UBE2QL1 (upper panel). When cotransfected with
myc-UBE2QL1 and either FBXW7 γ (middle panel) or FBXW7α (lower panel) and stained with antibodies against FBXW7α or FBXW7γ (red) and
myc (green) there was nuclear colocalization of UBE2QL1 with FBXW7α and FBXW7γ . Triple refers to DAPI nuclear staining (blue) and the merged
images together. B: HEK-293 cells were transfected with either myc tagged to an empty vector (myc-EV) or myc-UBE2QL1 and FLAG-FBXW7
as indicated. Immunoprecipitation (IP) of myc-UBE2QL1 (upper panel) followed by immunoblot (IB) analysis with antibody against the FLAG tag
identified FBXW7α and FBXW7γ as UBE2QL1 interacting proteins. The reciprocal experiment whereby IP of FLAG-FBXW7α and FLAG-FBXW7γ
(lower panel) followed by IB analysis with antibody against the myc tag also identified FBXW7α and FBXW7γ as UBE2QL1 interacting proteins.
Input levels of FBXW7α, FBXW7γ , and UBE2QL1 in the cell lysate are indicated.
Previously, the FBXW7/SCF complex was shown to target mTOR
for ubiquitylation and proteasomal degradation [Mao et al., 2008]
and mTOR activation is common in sporadic RCC and mTOR in-
hibitors have shown promise in clinical trials for the treatment of
metastatic RCC [Anandappa et al., 2010; Gerullis et al., 2010; Pinto
Marı́n et al., 2012]. We note that although VHL-inactivated RCC are
invariably clear cell, those associated with germline FLCN mutations
(causing Birt–Hogg–Dubé syndrome) and the t(5;19)(p15.3;q12)
represent a variety of histopathological subtypes indicating that
UBE2QL1 dysregulation, like FLCN, can drive tumorigenesis of
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Figure 6. UBE2QL1 facilitates the degradation of FBXW7 targets mTOR and CCNE1. A: 10 μg of protein lysate extracted from SKRC 47 and
SKRC 39 stable clones expressing pFLAG-CMV-4-wtUBE2QL1 (FLAG-UBE2QL1) and pFLAG-CMV-4 (FLAG-EV) were immunoblotted with antibodies
against both mTOR and CCNE1 and demonstrated a reduction in their expression in UBE2QL1 expressing cells as compared with the EV control.
Immunoblot controls for anti-ß-actin and anti-FLAG are also shown. B: HeLa cells were transfected with either myc tagged to an empty vector
(myc-EV) or myc-UBE2QL1 as indicated. Twenty-four hours post transfection, cells were treated with 100 μg/ml cyclohexamide (CHX) and collected
at the indicated times afterward. Upper panels, immunoblot analysis using antibodies against endogenous mTOR (left) and CCNE1 (right) indicated a
reduction in protein levels compared with that of the housekeeping protein, β-actin. Input level of UBE2QL1 in the cell lysate is shown. Lower panels,
relative densities of mTOR (left) and CCNE1 (right) to β-actin by densitometry, normalized to time point zero (unpaired t-test, error bars = SEM, n = 3,
∗P < 0.05).
different RCC subtypes. Furthermore, in accord with our findings
with respect to UBE2QL1, the FLCN gene product has been impli-
cated in mTOR pathway regulation [Baba et al., 2006; Chen et al.,
2008; Hasumi et al., 2009].
Recently Guo et al. (2011) undertook exome and targeted rese-
quencing in RCC and identified twelve previously unidentified genes
mutated at elevated frequencies in clear cell RCC. They highlighted
the role of mutations in components of the ubiquitin-mediated pro-
teolysis pathway (UMPP), and found an association between UMPP
mutations and dysregulation of HIF-1 and HIF-2. Our findings il-
lustrate how analysis of rare inherited forms of RCC can provide
candidate TSGs that would not be detected by exome resequenc-
ing studies (as somatic inactivation of UBE2QL1 occurred through
epigenetic silencing and deletions) and note that the absence of
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frequent intragenic UBE2QL1 mutations is reminiscent of RASSF1A
which is often inactivated by methylation/allele loss in sporadic RCC
[Dreijerink et al., 2001; Morrissey et al., 2001; Richter et al., 2009].
The absence of a detectable mechanism of inactivation in some tu-
mors showing UBE2QL1 downregulation, and the finding of two
distinct hits in just a minority of tumors, suggests that further alter-
ations affecting UBE2QL1 function, either of UBE2QL1 itself, or via
another component of the pathway, remain to be identified. Thus,
dysregulation of FH and SDHB can contribute to HIF-1α-mediated
pseudo-hypoxia driving RCC tumorigenesis through substrate in-
hibition of HIF-1α prolyl hydroxylation [Pollard et al., 2005] and,
more recently, the identification of TCEB1 (MIM #600788) (encod-
ing Elongin C) mutations in sporadic RCC [Sato et al., 2013].
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